Immune Therapeutics derivative called Cytocom has recently publicized a signing of a definitive merger agreement with Cleveland BioLabs. This merger will brand Cytocom and Cleveland BioLabs as a solitary public company trading as ( NASDAQ: CBLI ). The new company will be focused on the growth and commercialization of immunotherapies for oncology, infectious disease, inflammation and auto-immune mediated conditions. Immune Therapeutics, Inc. ( OTCMKTS: IMUN ) holds a substantial position in Cytocom. Immune Therapeutics ( OTCMKTS: IMUN ) believes the Cytocom platform technologies and product pipeline, in combination with Cleveland BioLabs, have the potential to drive substantial future progress in Immune’s shareholder value.
Immune Therapeutics, Inc. ( OTCMKTS: IMUN ) Cleveland BioLabs ( NASDAQ: CBLI ) New Video
As part of the 2014 spin off of Cytocom as a separate company, Immune accredited the rights to brand and sell therapeutics comprising of CYTO-201 and CYTO-401 in over 80 countries, including Brazil and China. Cytocom is now reacquiring this license in exchange for the $5 million of Immune liabilities. Cytocom’s prime trial drug candidate, CYTO-201, an immune modulator, is currently being studied in late-stage medical trials for Crohn’s Disease, Fibromyalgia, Multiple Sclerosis and the Human Immunodeficiency Virus (HIV) and is pending FDA approval of an Investigational New Drug Application (IND) for a Phase 2 study in COVID-19. CYTO-401 is being established as a cancer immunotherapy and antiviral therapy targeting HIV, as well as the H1N1 virus.
So today you have two public companies you can track due to this thrilling news – Immune Therapeutics, Inc. ( OTCMKTS: IMUN ) and its spinoff company Cytocom which is now merging with Cleveland BioLabs and is trading under the ticker symbol ( NASDAQ: CBLI ) If you like to learn more about Immune Therapeutics go to: ImmuneTherapeutics.com and Cytocom.com as well.
Immune Therapeutics, Inc. ( OTCMKTS: IMUN ) Spinoff Cytocom Inc. Appoints BioPharm Industry Veteran as New COO
WINTER PARK, Fla., Nov. 10, 2020 /PRNewswire/ — Cytocom, Inc. (Cytocom), a leading biopharmaceutical company in the area of immune-modulation, today announced that Taunia Markvicka, PharmD., MBA, has joined the company as Chief Operating Officer (COO). With more than 25 years of biopharmaceutical industry experience, Dr. Markvicka joins Cytocom as it plans for the potential global commercialization of novel immunotherapies developed with its AIMS (Advanced Immunomodulating Multi-Receptor System) drug discovery and development platform.
Industry veteran to lead corporate strategy and prepare for commercialization of Cytocom’s immune-modulating therapies developed with AIMS technology platform